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Key points
 Regulatory light chain (RLC) phosphorylation has been shown to alter the ability of muscle to
produce force and power during shortening and to alter the rate of force redevelopment (ktr)
at submaximal [Ca2+].
 Increasing RLC phosphorylation 50% from the in vivo level in maximally [Ca2+]-activated
cardiac trabecula accelerates ktr.
 Decreasing RLC phosphorylation to 70% of the in vivo control level slows ktr and reduces
force generation.
 ktr is dependent on sarcomere length in the physiological range 1.85–1.94 µm and RLC
phosphorylation modulates this response.
 We demonstrate that Frank–Starling is evident at maximal [Ca2+] activation and therefore
does not necessarily require length-dependent change in [Ca2+]-sensitivity of thin filament
activation.
 The stretch response is modulated by changes in RLC phosphorylation, pinpointing RLC
phosphorylation as a modulator of the Frank–Starling law in the heart.
 These data provide an explanation for slowed systolic function in the intact heart in response
to RLC phosphorylation reduction.
Abstract Force andpower in cardiacmuscle have a knowndependence onphosphorylation of the
myosin-associated regulatory light chain (RLC). We explore the effect of RLC phosphorylation
on the ability of cardiac preparations to redevelop force (ktr) in maximally activating [Ca2+].
Activation was achieved by rapidly increasing the temperature (temperature-jump of 0.5–20ºC)
of permeabilized trabeculae over a physiological range of sarcomere lengths (1.85–1.94µm). The
trabeculae were subjected to shortening ramps over a range of velocities and the extent of RLC
phosphorylation was varied. The latter was achieved using an RLC-exchange technique, which
avoids changes in thephosphorylation level of other proteins. The results show that increasingRLC
phosphorylation by 50% accelerates ktr by 50%, irrespective of the sarcomere length, whereas
decreasing phosphorylation by 30% slows ktr by 50%, relative to the ktr obtained for in vivo
phosphorylation. Clearly, phosphorylation affects the magnitude of ktr following step shortening
or ramp shortening.Using a two-statemodel, we explore the effect of RLCphosphorylation on the
kinetics of force development, which proposes that phosphorylation affects the kinetics of both
attachment and detachment of cross-bridges. In summary, RLC phosphorylation affects the rate
and extent of force redevelopment. These findings were obtained in maximally activated muscle
at saturating [Ca2+] and are not explained by changes in the Ca2+-sensitivity of acto-myosin
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interactions. The length-dependence of the rate of force redevelopment, together with the
modulation by the state of RLC phosphorylation, suggests that these effects play a role in the
Frank–Starling law of the heart.
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Abbreviations CF, conversion factor; DR, duty ratio; f, rate constant of cross-bridge attachment (s−1); F, force produce
by an individual cross-bridge (pN); F1.85, force of a maximally activated trabecula at a sarcomere length of 1.85 µm
(kN m–2); F1.90, force of a maximally activated trabecula at a sarcomere length of 1.90 µm (kN m–2); F1.94, force of
a maximally activated trabecula at a sarcomere length of 1.94 µm (kN m–2); Fiso, isometric force (kN m–2); FL s–1,
trabecula shortening velocity (trabecula lengths s–1); Framp, force sustained during a shortening ramp at a steady velocity
(kNm–2); Frec, force recovered in isometric conditions after the end of protocol (kNm–2); g, rate constant of cross-bridge
detachment (s−1); k1.85, rate of force redevelopment (ktr), at a sarcomere length of 1.85 µm (s−1); k1.90, rate of force
redevelopment (ktr), at a sarcomere length of 1.90 µm (s−1); k1.94, rate of force redevelopment (ktr), at a sarcomere
length of 1.94µm (s−1); ktr, rate of force redevelopment (s–1);N, number available cross-bridges for active cycling; RLC,
regulatory light chain; SL, sarcomere length (µm).
Introduction
Contraction in striated muscle is driven by interactions
between actin and myosin, and is controlled by the
availabilityof freeCa2+ tobind the thinfilament regulatory
complex (troponin complex). This ‘on/off’ mechanism
in striated muscle determines the availability of myosin
binding sites on actin (thin filament activation) (Moss
et al. 2004). In the presence of calcium, these sites are
available and cyclical interactions between actin andmyo-
sin occur, producing force and shortening. In addition,
RLC phosphorylation level plays a role in modulating
the ability of cross-bridges to produce force, especially
under load (Toepfer et al. 2013). What has not yet been
well established is the ability of RLC phosphorylation
to alter the kinetics of force redevelopment (ktr) (not
created by stretch activation) (Stelzer et al. 2006a; Stelzer
et al. 2006b) in cardiac tissue. Force redevelopment was
described in 1957 by Huxley using a simple two-state
model, which described ktr as the sum of the forward
(f), and backward (g) rate constants for the transition
into (and out of) the load bearing acto-myosin states,
respectively (Huxley, 1957). Thus, processes that affect f
or g modify the amplitude of force and the rate of force
redevelopment. The amount of isometric force produced
(Fiso) is given by:
Fiso = F · N · f /(f + g)
where F is the force per cross-bridge,N is the total number
of cross-bridges in the filament overlap region and f/(f+ g)
is the proportion of cross-bridges in force generating
states.
Subsequent studies have shown that the rate constants
f and g are complex terms, dependent on transitions
between multiple biochemical intermediates (Pate &
Cooke, 1986; Regnier et al. 1998). Although the two-state
model does not describe the transient force response
following step changes in length, it is a useful tool for
making comparisons between treatment groups (Huxley
& Simmons, 1971; Podolsky et al. 1976); for example,
the rate of ADP release from the myosin active site
was identified as both strain sensitive and a major
determinant of g in striated muscle (Nyitrai & Geeves,
2004; Greenberg et al. 2014). The rate of f is dependent on
thin filament activation (co-operative activation) (Bremel
& Weber, 1972; Brenner, 1988; Araujo & Walker, 1994;
Wolff et al. 1995), which in effect alters the availability
of actin binding sites to which myosin heads may bind,
a factor also considered to be influenced by lattice
expansion or shrinkage and by regulatory light chain
(RLC) phosphorylation, shifting the myosin heads closer
to the thin filament by addition of a negative charge to the
neck region (Barany et al. 1980; Ueno&Harrington, 1981;
Levine et al. 1996; Colson et al. 2010). Previous studies
investigating the effect of RLC phosphorylation on ktr and
on the stretch activation response in rat cardiac trabeculae
were performed using relatively long sarcomere lengths
(SL) (2.2–2.3 µm), in the presence of either limiting or
maximal [Ca2+], with conflicting results (Morano et al.
1995; Olsson et al. 2004; Stelzer et al. 2006b; Colson et al.
2010). Work on skeletal muscle in submaximal [Ca2+]
clearly identifiedRLCphosphorylation as adeterminant of
ktr (Metzger et al. 1989; Sweeney & Stull, 1990). However,
the role that RLC phosphorylation plays in regulating ktr
in cardiac muscle after shortening and at physiological
sarcomere lengths observedduring systole (1.91–1.68µm)
(Sonnenblick et al. 1967) is unknown.
By carrying out experiments in the presence of
saturating [Ca2+], the effect of calcium-dependent
activation is eliminated such that any changes in ktr depend
on the RLC phosphorylation levels and not on the calcium
regulatory complex (de Tombe & Stienen, 2007). The role
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of RLC phosphorylation warrants investigation because
the observed changes in RLC phosphorylation levels in
myocardium, above or below basal levels, change both
power output and force production of the tissue (Toepfer
et al. 2013) Additionally, there is a close association
between RLC phosphorylation and myocardial function,
such as in disease models, both acquired and inherited
(Sheikh et al. 2014).
In the present study, we use an in vitro RLC exchange
protocol to alter RLC phosphorylation level in rat cardiac
ventricular trabeculae, without affecting phosphorylation
of other sarcomeric constituents (Toepfer et al. 2013).
Activation of the permeabilized trabeculae is achieved
by temperature-jump to ensure rapid and homogeneous
activation and thereby avoiding the confounding effects
of Ca-diffusion into the core of the trabeculae. We
measure ktr using a step release protocol at three physio-
logical RLC phosphorylation levels that are observed in
health and disease (Sheikh et al. 2014). This provides a
measurement of absolute force redevelopment when all
cross-bridges are primed to begin actively cycling after
being forcibly detached by a rapid release. Measurements
are carried out at three sarcomere lengths (SL, 1.94, 1.90
and1.85 µm), with the shortest being that encountered
during late systole in vivo (Guccione et al. 1997; Hanft
et al. 2008). We use release-ramp protocols to elicit
force redevelopment to measure ktr over a range of
physiological shortening velocities that the intact myo-
cardium would encounter during systole. This technique
allows us to assess ktr with unsynchronized cross-bridges
populating a variety of cross-bridge states, similar to that
occurring in the shortening myocardium during systole.
Hence, we aim to advance our mechanistic understanding
of how RLC phosphorylation alters ktr, independently
of calcium-dependent co-operative activation in cardiac
muscle.
Methods
Ethical approval
All animal procedures were carried out in accordance with
the Guide for the Care and Use of Laboratory Animals,
published by the United States National Institutes of
Health, under assurance number A5634-01. Cervical
dislocation was performed in accordance with Schedule
1 of the UK Home Office Animals (Scientific Procedures)
Act 1986.
Trabeculae preparation
Female Sprague–Dawley rats (fed ad libitum) weighing
250–350 g were anaesthetized using isofluorane
inhalation, until unconscious. Rapid cervical dislocation
was followed by removal of the heart by abdominal
and subsequent thoracic resection. Hearts were excised
with intact aortic arches for cannulation and retrograde
perfusion with oxygenated ice-cold Krebs–Henseleit
solution (composition in mM: 119 NaCl, 4.7 KCl, 0.94
MgSO4, 1 CaCl2, 1.2 KH2PO4, 25 NaHCO, 11.5 glucose
and 30 2,3-butanedione monoxime, in addition to
12 units ml–1 of heparin). Left ventricular trabeculae
(1–2 mm in length and 100–300 µm in width) were
excised from the resected left ventricle. Trabeculae ends
were then crimped in T-clips and pinned at resting
length on Sylgard for chemical permeabilization using
relaxing solution (composition in mM: 60 TES, 8.66
MgCl2, 20 EGTA, 5.43 Na2ATP, 10 glutathione and 33.71
potassium propionate at pH 7.4) for 30 min at 5°C,
incorporating 2% Triton X-100. Trabeculae were stored
post-permeabilization at –20°C in 50% relaxing solution
with 50% glycerol and protease inhibitors (4 mg l–1
leupeptin, 10 mM phenylmethanesulphonyl fluoride and
50mg l–1 trypsin inhibitor). Trabeculae were stored for no
longer that 3 days prior to experimentation.
RLC exchange
The methods for exchange and for measuring the
extent of exchange have been described previously
(Toepfer et al. 2013). Briefly, recombinant cardiac RLC
from Rattus norvegicus was expressed, purified and
dephosphorylatedorphosphorylated in vitrousing shrimp
alkaline phosphatase or smooth muscle myosin light
chain kinase, respectively (Toepfer et al. 2013). RLCs with
known phosphorylation levels (0.1 mol Pi mol–1 RLC,
0.5 mol Pi mol–1 RLC and 1.1 mol Pi mol–1 RLC) were
exchanged for native RLC in permeabilized trabeculae
using an exchange buffer (composition in mM: 5 ATP, 5
EGTA, 5 EDTA, 10 imidazole, 150 potassium propionate,
10 KH2PO4, 5 DTT and 0.5 trifluoperazine at pH 6.5).
Exchange was performed with 0.6 mg ml–1 RLC on the
experimental set-up at a sarcomere length of 2.1 µm at
0.5°C for 45 min. The extent of RLC phosphorylation
in the trabeculae was calculated from the measured
time course of RLC exchange (Toepfer et al. 2013).
Exchange protocols were adjusted to obtain three RLC
phosphorylation levels in trabeculae. Thesewere increased
phosphorylation (phosphorylated) with a normalized
RLC phosphorylation of 1.5 ± 0.1 (0.66 mol Pi mol–1
RLC) compared to native where the extent of
phosphorylation is 0.44 mol Pi mol–1 RLC, reduced
phosphorylation of 0.7 ± 0.05 (0.31 mol Pi mol–1
RLC) and control exchange mimicking native RLC
phosphorylation levels of 1.1 ± 0.1 (Toepfer et al. 2013).
Trabeculae mechanics
After exchange, the ends of the trabeculae were attached
to the apparatus with shellac and the sarcomere length
was adjusted to 2.1 µm, using the first-order sarcomere
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Table 1. Experimental solutions
Relaxing Pre-activating Activating
(pH 7.1) (pH 7.1) (pH 7.1)
Tes 100 100 100
MgCl2 7.8 6.8 6.5
Na2ATP 5.7 5.7 5.7
EGTA 25 0.1 0
GLH 20 20 20
HDTA 0 24.9 0
CaEGTA 0 0 25
All concentrations are in mm. pH was set for the specific
temperature of the solution used. GLH, glutathione; HDTA,
1,6-diaminohexane-N,N,N′,N′-tetraacetic acid.
diffraction line visualized by illumination with a HeNe
laser. Contraction was triggered by a temperature-jump
method where the preparation cycles through a series of
solutions at high (20°C) and low (0.5°C) temperatures
to activate and relax muscle contraction, respectively
(Toepfer et al. 2013). The protocol consists of: (1) relaxing
solution at 0.5°C, where no force is seen, apart from
that as a result of resting tension; (2) pre-activation
solution 0.5°C; (3) activating solution 0.5°C,where, at this
temperature, only a little force develops (<5% of that at
20°C); (4) activating solution 20°C (shortening protocols
are applied once isometric plateau is reached); and (5)
and relaxing solution 20°C, where force decreases back to
zero. The preparation is then returned to relaxing solution
at 0.5°C and the cycle is repeated. Solution compositions
are shown in Table 1. The sarcomere length was rechecked
at the end of each experiment to ensure that no slippage
had occurred. Each trabecula went through up to nine
activationcycleswithout showing significantdeterioration
of force. Each trabecula was tested at several shortening
ramp velocities (see below).
Two mechanical perturbation protocols were used in
the experiments described in the present study. The first
protocol consists of a rapid (step release) reduction in
trabecula length, applied during the plateau of isometric
force development at 20°C, starting at a sarcomere length
of 2.1 µm. The speed and amplitude of the applied
release is such that the trabecula becomes momentarily
slack. Following the release, force re-develops. Force
re-development is characterized in terms of the amplitude
of force regained and the rate constantdescribing the speed
of force redevelopment.
The second protocol, ‘release-ramp’, consists of a small
and fast step release, followed by a slower decrease in
trabecula length at a steady shortening velocity at 20°C.
The step release unloads the instantaneous elasticity of
the preparations and the ramp shortening allows the
trabecula to reach a steady tension, which is characteristic
for the ramp velocity, thus defining the force–velocity
relationship. The effects of RLC phosphorylation on the
force–velocity relationship have been reported previously
(Toepfer et al. 2013). In the present study, we use the
protocol to explore the redevelopment of force following
the period of steady shortening. As in the ‘step release’
protocol, two parameters are measured: the amount of
force regained and the rate of force redevelopment. Details
of the two protocols are given below.
Step release protocol
Each trabeculapreparationdevelopedpeak isometric force
at a sarcomere length of 2.1 µm. Rapid length changes,
which were faster than the maximal shortening velocity of
the unloaded preparation, were applied to the trabeculae,
with shortening amplitudes of –8% (end-point sarcomere
length: 1.94 µm), –10% (1.90 µm) and –12% (1.85 µm)
of the initial sarcomere length (2.1µm) during activation.
Isometric force redeveloped at each nominal sarcomere
length, with an amplitude denoted as F1.94, F1.90, and F1.85.
A representative force trace for a –8% step is shown in
Fig. 1A. Figure 1B shows the length transducer signal
for shortenings at each of the three amplitudes. Each
force recovery time-course was fit with a two-parameter
exponential:
F = F rec (1 − e−ktr(t))
whereFrec is the steady-state force recoveredpostprotocol,
F is the force at time t and ktr is the rate of force
redevelopment post protocol.
The exponential was applied from t = 0, which was the
timeatwhich forcewasdiscernibly above zero (F=0).This
time point was when the slack had been taken up by active
shortening of the trabeculae to the new lower sarcomere
length (Fig. 1C). Figure 1D shows the exponential fit to
three representative traces for force re-development by the
same trabecula at three sarcomere lengths. The fitted rate
constants were k1.94 = 10 s–1, k1.90 = 9 s–1 and k1.85 = 8 s–1.
Figure 1E shows the scatter of residuals for the fit to plots
in Fig. 1D. This protocol was applied to each trabecula at
each RLC phosphorylation level.
Release-ramp protocol
The release-ramp protocols were designed to determine
the force-velocity relationship in trabeculae for a range
of RLC phosphorylation levels. A byproduct of these
protocols is the time-course of force recovery following the
period of shortening, which we find to be sensitive to RLC
phosphorylation levels, providing information about the
kinetics of actomyosin interactions. Isometric force was
allowed to develop at a sarcomere length of 2.1µm. At the
plateau of isometric force, the length transducer applied
a rapid shortening to the trabecula, followed by a slower
shortening (Fig. 2A). Depending on the ramp velocity, the
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Figure 1. Step-release protocol on control trabecula
A, time course of force changes (black) of a trabecula following temperature-jump activation. Isometric force (Fiso)
is reached before an 8% step release is applied. Force recovery after the release is fit with a single exponential (Blue
& McMurray, 2005). B, representative motor output traces showing the step protocols for step release protocols of
three different amplitudes. C, expanded force trace directly after step-release. Time zero is set to be the time after
the end of the step release when force deviated from zero (F = 0). D, representative force recoveries observed
after step releases of variable amplitude leading to different sarcomere lengths after the end of the step release.
Each plot is fit with a single exponential (continuous lines). E, plot of residuals for each slack protocol performed
in (D).
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amplitude of the initial rapid release length was altered to
minimize series elasticity during ramp, which resulted in a
relatively stable force signal during ramp release (Fig. 2D).
This protocol provides a reliable method for determining
the experimental relationship between force and velocity
(Curtin et al. 1998). Ramp velocities of 1, 0.5 and 0.3 FL s–1
were applied, where the velocity is expressed as fibre
lengths per second (FL s–1), with fibre length being the
length of the trabecula between the T-clips when held at
a sarcomere length of 2.1 µm. The parameters describing
the length change protocols are given in Table 2.
Each protocol reduced sarcomere length by 8% to
1.94 µm. Figure 2B shows representative traces of the
force developing after the end of the ramp, starting at
a sarcomere length of 1.94 µm. Isometric force reached
after each ramp is given as F1, F0.5 and F0.3, where
the subscript denotes the shortening velocity during the
release ramp. Figure 2C shows the scatter of residuals
for the exponential fit to the force data in Fig. 2B.
Figure 2D shows the force records during the release-ramp
protocols including the subsequent force redevelopment,
for trabeculae incorporating RLC at three different
phosphorylation levels. The higher the phosphorylation
level of the sample, the higher the force attained during
initial force development at a sarcomere length of 2.1 µm
(Fiso) and during ramp (Framp). The fit to the force
recovery records after ramp shortening gave estimates
for the rate constant describing the time-course of force
redevelopment. The rate constants were obtained for
force recovery following ramps at three different velocities
(see above) and are therefore denoted k1, k0.5 and k0.3
for the three ramp velocities of 1, 0.5 and 0.3 FL s–1.
These rate constants were calculated for each of the three
phosphorylation states.
2
2
1
0
–1
–2
0
0
–2
–4
–6
–8
–10
70
60
50
40
20
30
10
0
20
18
16
14
12
10
8
6
4
2
0
200 400 600 800 –400 –200 0 200 400 600 800 1000
Time (ms)Time (ms)
0 200 400 600 800
Time (ms)
Ramp
Fiso
Framp
Frec
begin Ramp end
0 50 100 150 200
Time (ms)
Residuals 1 FL/s
Force production after 1 FL/s ramp
Force production after 0.5 FL/s ramp
Force production after 0.3 FL/s ramp
Rapid release and 1 FL/s ramp
Rapid release and 0.5 FL/s ramp
Rapid release and 0.3 FL/s ramp
Phosphorylated
Control phosphorylation
Reduced phosphorylation
Residuals 0.5 FL/s
Residuals 0.3 FL/s
F
ib
re
 le
ng
th
 (
%
)
F
or
ce
 (
kN
/m
2 )
F
or
ce
 (
kN
/m
2 )
F
or
ce
 (
kN
/m
2 )
A
C D
B
Figure 2. Release-ramp protocols
A, time course of length changes of varying speed and amplitude applied to trabeculae by the length transducer.
The differences between 0.3, 0.5 and 1 FL s–1 release velocities are seen. B, time course of force recovery (Frec)
after release-ramp protocols of different velocities. Each force recovery is fit with a single exponential. C, plot of
residuals for each release ramp protocol shown in (B). D, time course of force changes from three trabeculae at
differing RLC phosphorylation levels, induced by the slowest ramp shown in (A). The force signals show that the
force level during the fixed velocity ramp (Framp) depends on the RLC phosphorylation level. Phosphorylation also
affects the ability of trabeculae to recover force after the end of the ramp-release (Frec).
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Table 2. Experimental release-ramp protocol for each ramp
velocity
Ramp release Release amplitude Ramp amplitude
(FL s–1) (% trabecula length) (% trabecula length)
1.0 3% 5%
0.5 3% 5%
0.3 2% 6%
All protocols released to a maximum of 8% of initial muscle
length. The breakdown of the release-ramp amplitudes for each
velocity protocol is shown
Modelling a two-state cross-bridge cycle
The model considers:
R <−> A
where R is the relaxed state and A is the active,
force-generating state.The rate constants f and gdetermine
transition into the force-generating state and into the
relaxed state, respectively.
In such a model, the amount of force at any time (t) is
given by a single exponential equation as:
Y = [fxN/(f + g)] × [1 − e(−(f +g)×T)]
where Y is the amount of force generating cross-bridges,
N is the total concentration of cross-bridges and T is time.
The fraction of actin-attached cross-bridges is given by
Y/N, which is also referred to as the duty ratio (DR).
According to this model, the rate constant describing
force generation is (f + g). The rate of force development
observed in the experiments described in the present study
thus give estimates for (f+ g) under various conditions of
RLCphosphorylation and sarcomere length. The observed
time course of force generation is well described by a single
exponential process (Fig. 1D and E and Figs 2 and 3).
For any given muscle type at full isometric activation,
the DR is constant, which was approximated as 50% at
control phosphorylation (He et al. 2000). This is 100 µm
of myosin heads out of the 200 µm available to form
cross-bridges. To convert DR into a force measurement,
we consider an empirical conversion factor (CF) given by:
CF = Fiso/DR
The CF was assumed to be constant between RLC
phosphorylation levels.
This allowed the calculation of DR for each sarcomere
length and RLC phosphorylation level. Knowing ktr, Fiso
and CF allowed for the calculation of g and f as:
g = (CF − Fiso) × (ktr/CF)
f = ktr − g
CalculatingDR for each RLC phosphorylation level and
SL allowed the approximation of force per cross-bridge
(FXB), which is given by:
FXB = Fiso/ (total heads × DR)
FXB (in pN) and the total number of heads were derived
byassuminga constant concentrationof 200µmofmyosin
heads (Ferenczi et al. 1984).
The modelling results are shown in Table 3.
Statistical analysis
We hypothesized that: (i) RLC phosphorylation
and (ii) sarcomere length affected ktr at maximal
calcium activation. Multiple comparisons between RLC
phosphorylation groups and protocols were made using
two-way ANOVA to test experimental hypotheses. The
hypotheses tested were (i) that SL affected ktr and (ii)
that RLC phosphorylation affected ktr. Appropriate post
hoc pairwise multiple comparisons were made using
Bonferroni adjusted t tests, with a statistical significance
cut-off of P < 0.05. SigmaPlot (Systat Software Inc.,
Chicago, IL, USA) was used to perform statistical
analysis. N is the number of trabeculae sampled for each
protocol. Each treatment group comprised of five cardiac
preparations.
Results
The effect of RLC phosphorylation on the rate of force
redevelopment and force level after step release
Measuring force redevelopment from slack allows the
assessment of force production from a state where many
of the cross-bridges will be synchronized in the unbound
and weakly bound states (diastole). Therefore, inferences
can be made about the attachment and detachment
kinetics of myosin and how these parameters can be
altered by SL, as well as RLC phosphorylation. Force
redevelopment from slack at sarcomere lengths of 1.94 ,
1.90 and 1.85 µm was measured for three different
RLC phosphorylation levels (Fig. 3). These SL were
used to minimize passive tension and to simulate the
SL lengths that are transitioned through in late systole
(Sonnenblick et al. 1967). For SL = 1.94 µm (Fig. 3A),
the extent of force recovery was higher at higher levels
of RLC phosphorylation, and reduced by decreasing RLC
phosphorylation. Trabeculae with control levels of RLC
phosphorylation produced an isometric force at a SL of
1.94 µm (F1.94) of 63 ± 5 kN m–2 (Fig. 4C). This was not
significantly different from trabeculae with increased RLC
phosphorylation (78 ± 7 kN m–2) but was higher than in
trabeculae with reduced phosphorylation (16± 4 kNm–2;
P < 0.05). This was unsurprising because we have shown
this phenomenonpreviously (Toepfer et al. 2013). The rate
C© 2016 Wellcome Trust The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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constant describing force redevelopment, with a starting
sarcomere length of 1.94 µm (k1.94), was also affected
by RLC phosphorylation. Unlike force, ktr is affected
in a dose-dependent fashion by RLC phosphorylation
where control levels of RLC phosphorylation show an
intermediate rate of k1.94 11 ± 1.7 s–1, to increased and
reduced phosphorylation k1.94 24 ± 1.8 and 7.2 ± 0.9 s–1
respectively, with both being significantly different from
control (P < 0.05) (Fig. 3B). At the shorter sarcomere
lengths of 1.90 and 1.85 µm, differences in isometric
force between control trabeculae and phosphorylated
trabeculae were not observed (Fig. 3C and E and Fig. 4C).
However, in both instances, trabeculae with reduced
RLC phosphorylation exhibited a significantly lower force
when compared to control and phosphorylated samples
at a SL of 1.94 µM (P < 0.05). Phosphorylation level
similarly affected the rate of force redevelopment at shorter
sarcomere lengths in a manner the same as that for the
longer starting sarcomere length of 1.94 µm (P < 0.05)
(Fig. 4). Therefore, the affect of RLC phosphorylation on
ktr is an independentmodulator of ktr, which is not altered
by SL in this range. Strikingly, at a sarcomere length of
1.85 µm, trabeculae with reduced RLC phosphorylation
(70% of control) generated only a small amount of force
(10–15%) compared to the values at control and 150%
phosphorylation. (P < 0.05). The reason for this effect is
unclear. However, reducing RLC phosphorylation reduces
the ability of muscle to generate force at full thin filament
activation, indicating that either force per cross-bridge or
cross-bridge formation is significantly hindered.
Normalizing to the isometric force at each sarcomere
length highlights the effect of RLC phosphorylation on ktr
by allowing a direct comparisonof the time-course of force
redevelopment at each phosphorylation level (Fig. 3B, D
andF). This highlights the role of RLCphosphorylation on
force redevelopment at the three physiological sarcomere
lengths tested (Fig. 4A).
Additionally, for each RLC phosphorylation level, ktr
is slower at shorter sarcomere lengths (Fig. 4B). The
gradients of linear regressions applied to the data in
Fig. 4B were 79 ± 14, 8 ± 0.2 and 26 ± 3 s−1 µm−1
for phosphorylated, control phosphorylation and reduced
phosphorylation, respectively (n = 5). Statistical signifi-
cance was observed between each slope (P < 0.05).
The effect of RLC phosphorylation on the rate
of force production and extent of redeveloped force
after release-ramp protocols
Trabeculae with one of three different RLC
phosphorylation levels underwent release-ramp
shortening protocols during activation at 20°C to a
final sarcomere length of 1.94 µm (8% total shortening).
Release-ramp shortening simulates active cross-bridge
cycling at different muscle loads, which would be
C© 2016 Wellcome Trust The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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encountered during systole. At the end of these
manoeuvres, force redevelopment occurs in mixed
populations of cross-bridge states, unlike the release
protocol, which synchronizes allmyosin heads intoweakly
(or unbound) states. This assay allows us to assess whether
changes in ktr can be attributed to enhanced thin filament
activation by already bound cross-bridges. The shortening
velocities were 1, 0.5 and 0.3 FL s–1 (Fig. 5A, C and E),
where 0.3 redevelops force from the highest muscle load
with the most attached cross-bridges, by proportion.
For each RLC phosphorylation level, Fiso was constant
across all ramp velocities (Fig. 6C). This was expected
because Fiso was attained at a SL length of 1.94 µm
after each manoeuvre velocity. Trabecular preparations
with reduced RLC phosphorylation displayed a reduced
Fiso post release (independently of release velocity) of
19± 2 kNm–2 (P< 0.05) versus control of 49± 4 kNm–2
and phosphorylated of 55 ± 3 kN m–2 (Fig. 6C).
Normalizing force development at each RLC
phosphorylation level for each ramp velocity illustrates
the effect of RLC phosphorylation on the rate of
force rise (Fig. 5B, D and F). Trabeculae with control
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RLC phosphorylation displayed rate constants for force
production of 12 ± 1.2, 11 ± 1.1 and 10 ± 0.5 s–1 at
velocities of 1, 0.5 and 0.3 FL s–1 respectively (Fig. 6B
and Table 4). Force rose more quickly for trabeculae
with increased RLC phosphorylation compared to control
(P < 0.05) at 21 ± 1.6, 19 ± 1.7 and 18 ± 1.6 s–1 for
velocities of 1, 0.5 and 0.3 FL s–1, respectively. Trabeculae
with reduced RLC phosphorylation had slower rates of
force production compared to control (P < 0.05) with
rates of 10 ± 3.2, 7.6 ± 0.8 and 6.7 ± 1.1 s–1 at velocities
of 1, 0.5 and 0.3 FL s–1, respectively.
Clearly, ktr is altered by RLC phosphorylation level
change at saturating [Ca2+] (Fig. 6A and Table 4).
The effect is seen for force redevelopment after ramp
shortening at all ramp velocities, although the effect of
ramp velocity itself is small and does not reach statistical
significance. This may infer that additional thin filament
activation by cross-bridge binding is either a small or
insignificant effector of ktr in this assay, and that changes
in ktr are associated with mechanisms involving thick
filament regulation andnot thin filament regulationunder
these experimental conditions.
Discussion
RLC phosphorylation is known to be important in many
elements of cardiac physiology and disease, including in
cardiac developmental organization (Nishio et al. 1997;
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Figure 6. The effect of RLC phosphorylation on ktr following the release-ramp protocol
A, the rate of force redevelopment ktr as a function of normalized RLC phosphorylation at SL = 1.94 µm
following ramp shortening at three velocities. Reduced phosphorylation is 0.69 ± 0.04, control phosphorylation
is 1.13 ± 0.07 and phosphorylated is 1.45 ± 0.1. ∗Significant difference compared to phosphorylated, where
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Table 4. Parameters from exponential fit of release-ramp protocol
Phosphorylated (n = 5) Control phosphorylation (n = 5) Reduced phosphorylation (n = 5)
Release velocity (µm) 0.3 0.5 1 0.3 0.5 1 0.3 0.5 1
Fiso 55 ± 3† 54 ± 2† 57 ± 4† 49 ± 4 47 ± 3 50 ± 4 19 ± 2 18 ± 2 17 ± 2
ktr 18 ± 1.6† 19 ± 1.7† 21 ± 1.6† 10 ± 0.5 11 ± 1.1 12 ± 1.2 6.7 ± 1.1 7.6 ± 0.8 10 ± 3.2
†Denotes a significant effect of RLC phosphorylation within a SL length (P < 0.05).
Okamoto et al. 2006), in regulation of ventricular torsion
(Davis et al. 2001; Hidalgo et al. 2006), and in acquired
(Aoki et al. 2000; Gu et al. 2010) and inherited diseases
(Sanbe et al. 1999; Ding et al. 2010; Sheikh et al. 2012;
Warren et al. 2012). Of note, the atria and ventricles have
separate isoforms of the RLC, and different mammals
have different RLC sequences with different numbers
of phosphorylatable residues. Accordingly, care needs to
be taken when comparing results from different species
(Morano, 1992).
We have previously demonstrated the ability of
RLC phosphorylation to influence myocardial force
production, power and shortening under-load (Toepfer
et al. 2013). Previous studies have probed the effect of
RLC phosphorylation on ktr, but have not assessed physio-
logical sarcomere lengths, and have shown conflicting
results (Olsson et al. 2004; Colson et al. 2010). In
the present study, we add clarity by showing that, at
maximal activation, RLC phosphorylation and, to a lesser
extent, sarcomere length alter ktr. The observed changes
are consistent with the Frank–Starling law of the heart
and may indicate a new mechanism that contributes to
this phenomenon (discussed below). Importantly, our
measurements at saturating calcium allow us to consider
processes that are independent of the Ca2+-dependent
contributions to theFrank–Starling law, andalso show that
RLC phosphorylation and the thick filament contribution
both play a role in the Frank–Starling law.
The effect of sarcomere length on the rate of force
production
Our measurements of ktr in control phosphorylation are
in the range observed in previous studies at maximal
activation between 4.5 and 14 s−1 with variance as
a result of changes in temperature and muscle type
(Wolff et al. 1995; Fitzsimons et al. 2001; Regnier et al.
2004). Additionally, ktr at control phosphorylation levels
(10–11 s−1) is close to the ATPase rate in trabeculae from
rats under identical experimental conditions (8 s−1)
(Mansfield et al. 2012).
Increasing sarcomere length from 1.85 to 1.94 µm
accelerated ktr at each RLC phosphorylation level. The
acceleration of ktr with stretch, independently of [Ca2+], is
observed in intact myocardium (Rhodes et al. 2015) and is
a calcium independentmanifestation of length-dependent
activation (de Tombe et al. 2010). This is in agreement
with the length–tension relationship of trabeculae from
rat because the sarcomere lengths used in the present
study are in the ascending limb of the length–tension
curve (Kentish et al. 1986). Some previous studies have
shown that ktr decreased between SLs of 2.0 and 2.35 µm
(Korte & McDonald, 2007; Patel et al. 2012) or had no
statistical effect (Adhikari et al. 2004; Hanft & McDonald,
2010), as well as between 2.0 and 2.2 µm (Milani-Nejad
et al. 2013). The differences between these findings and
those reported in the present study could conceivably
be a result of the SLs assessed or the technique used
to assess ktr because the aforementioned studies used
restretch protocols. The common interpretation of the
Frank–Starling law is that, with higher pre-loads, themyo-
cardium develops a greater systolic force as a result of
calcium-sensitive length-dependent activation, as well as
changes in myofilament overlap (Katz, 2002; de Tombe
et al. 2010). In accordance with Frank–Starling, our
data suggest that the force of contraction increases with
pre-load (an increased stretch ofmyocardium as a result of
increased chamber volume is accompanied by increases in
SL).Additionally, ourdata show that the rate atwhich force
is produced is also affected, although this phenomenon
only appears to be evident in situations where RLC
phosphorylation is raised or lowered from control levels
(Table 3). This phenomenon is beneficial to the ejection
fraction because the systolic duration would not need to
be prolonged to fully accommodate extra expulsion: ktr
accelerates to compensate for increased ejection volume.
Because this effect is observed at saturating [Ca2+], it is
independent of calcium-sensitive activation and the thin
filament regulatory complex. Thus, the measured changes
in ktr are explained by direct interactions between myosin
and actin that are independent of thin filament activation
and may be a consequence of the increase in f, which
will alter the distribution of actomyosin states towards
strongly-bound, force-generating states.
The effect of RLC phosphorylation on the rate
of force production
Our results show that RLC phosphorylation level alters
ktr over a range of SLs (1.85–1.94 µm) during maximal
calcium activation, in contrast to the findings of another
study at a higher SL (2.3 µm), which observed no
C© 2016 Wellcome Trust The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
14 C. N. Toepfer and others J Physiol 000.0
change to ktr at this higher SL (Olsson et al. 2004). The
difference in experimental result is probably a result of
the aforementioned differences in SL, possibly because ktr
is influenced by inter filament spacing, which is altered
by the length of the muscle (Wang & Fuchs, 1995).
Ourmeasurements at the shorter, physiological sarcomere
lengths are probably more meaningful during systole
(Sonnenblick et al. 1967), although saturating [Ca2+] and
the less than physiological temperaturemay also influence
the ability to extrapolate our findings to the situation
in the living animal.
Our measurements are made in saturating [Ca2+];
therefore, RLC phosphorylation must be altering
cross-bridge behaviour independently of the thin filament
regulatory complex. Consequently, RLC phosphorylation
modulates the Frank–Starling law of the heart (although
not on a beat to beat basis) (Stracher, 1969). We propose
that RLC phosphorylation level is another mechanism by
which the myocardium modulates its ability to redevelop
force in response to increased ventricular pre-load.
Interestingly, under chronic raised pre-load, RLC
phosphorylation is raised as a compensatory mechanism
to greater ventricular volume (Hidalgo et al. 2006),
providing further evidence that RLC phosphorylation is
an important modulator of systolic ejection in the intact
organ. Additionally, experimental models with reduced
RLC phosphorylation display increased systolic duration
and slowed cross-bridge kinetics, in accordance with our
findings (Abraham et al. 2009; Scruggs et al. 2009).
The use of constitutive RLC pseudophosphorylation to
correctRLCphosphorylation reductionhas been shown to
alleviate this phenomenon (Yuan et al. 2015). By contrast,
hyperphosphorylation of RLC increases contractility
and contractile efficiency independently of any disease
phenotype (Huang et al.2008).Together, thesefindings are
complementary to our own. Dephosphorylation of RLC
slows ktr, which prolongs systole: pre-load ejection takes
longer because systolic contractile kinetics are slowed.
Similarly a raised ktr as a result of RLC phosphorylation
explains increased ejection characteristics as cross-bridge
recruitment is accelerated by RLC phosphorylation.
Modelling of cross-bridge attachment (f)
and detachment (g)
We note that the rate of force redevelopment, ktr, was well
described by fitting a single exponential to the force signal
(Brenner, 1986; Metzger et al. 1989; de Tombe & Stienen,
2007). This justifies the application of a simple two-state
model to delve into the attachment and detachment
kinetics giving rise to the measurable ktr. In the two-state
model of the cross-bridge cycle, ktr is represented by
the sum of the two rate constants, f and g (Huxley,
1957). Although the two-state model is a simplistic
approximation to cross-bridge behaviour (Huxley &
Simmons, 1971; Podolsky et al. 1976), it is a useful tool for
exploring the effect of RLC phosphorylation. Modelling
of control tissue resulted in values of f and g that are
comparable to previous studies reported in the literature
(Brenner, 1988; Prakash et al. 1999; Prakash et al. 2000).
The model provides values for f, g, DR and FXB, which
describe our experimental findings (Table 3).
The modelling suggests that RLC phosphorylation
accelerates f, probably as result of a closer myosin head
proximity to actin (Levine et al. 1996; Colson et al.
2010). The model also calculates a modest acceleration
of g with increasing RLC phosphorylation. Changes to
g manifest as changes in the ratio between ATPase and
isometric force (Huxley, 1957). Indeed, it was shown
that myosin light chain kinase treatment increased myo-
sin ATPase and did not alter isometric force, in keeping
with this modelling outcome (Muthu et al. 2012). At
higher RLC phosphorylation, g is accelerated and the
peak isometric force was stable. The modelling outcome
is supported experimentally as the acceleration of f must
be greater than the acceleration of g, otherwise isometric
force would fall as phosphorylation increases (Regnier
et al. 2000). When comparing trabeculae with reduced
and increased phosphorylation, the rate of f is accelerated
20 fold at each SL, whereas g is only accelerated 1.6
fold. A recent study suggests that RLC phosphorylation
slows cross-bridge detachment (g), which does not fit the
modelling of our experimental data and contradicts the
existing literature (Pulcastro et al. 2016). The discrepancy
may result from the different experimental and modelling
approaches for the study of cross-bridge kinetics. The lack
of experimental records in this publication, as well as
the apparent very low isometric force, makes it difficult
to explore the source of the discrepancy. Perhaps the
phosphorylation state of other sarcomeric proteins is also
different from that achieved in thepresent study (Pulcastro
et al. 2016).
In our experiments, reduced RLC phosphorylation
levels are accompanied by reductions in Fiso and ktr. The
relative reduction of Fiso in the trabeculae with reduced
RLC phosphorylation compared to control is greater
(75%) than the reduction in ktr (30%). This may be
accounted for by a shift towards the super relaxed state
of the myosin heads (Hooijman et al. 2011), reducing
N. It is probable that either one (or both) of f and the
myosin ATPase rate must be altered by reduced RLC
phosphorylation to account for this reduction of force.
Our modelling estimates a marked 5-fold reduction in
f in the reduced phosphorylation cohort, which, again, is
probably explained by myosin proximity to actin (Colson
et al. 2010).
Our findings cannot rule out the possibility of
additional thin filament co-operativity induced by myo-
sin binding, even in the presence of saturating calcium
(Regnier et al. 2004). Similarly, acceleration of force
C© 2016 Wellcome Trust The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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redevelopmentmaywell be achieved by othermechanisms
that affect f, such as the unitary force of each cross-bridge
and the neck region stiffness, or indeed a change in the
size of the working stroke under load, which cannot be
accounted for by a two-state model (Nyitrai & Geeves,
2004; Greenberg et al. 2009; Karabina et al. 2015).
Our modelling suggests that FXB is not altered by RLC
phosphorylation. However, this could be an unavoidable
artefact of necessary assumptions in our modelling;
namely,N remains constant at each RLC phosphorylation
level,whichwecannotdirectly address in thepresent study.
However, in skeletal muscle, it was found that FXB and
N were not altered by phosphorylation, which may also
translate to cardiac muscle (Sweeney & Stull, 1990). Our
calculated value of FXB is comparable to that calculated
previously in other studies: 1.25–7 pN with an average of
3 pN between these studies, which is in good agreement
with our approximation from modelling (Ishijima et al.
1996; Takagi et al. 2006) (Ishijima et al. 1996; Nag et al.
2015).
A strikingfindingof ourmodelling is that SL affected ktr,
f and g; additionally, stretch influenced the transition from
weakly to strongly bound cross-bridges more than the
transition fromstrongly toweakly bound.This asymmetry
suggests a role for lattice spacing effects. Bringing myosin
heads closer to actin accelerates f at the same time as having
a smaller effect on g.
The findings of the model reported in the present
study are compatible with our previous findings using
force velocity and power velocity relations to assess
the effect of RLC phosphorylation on cardiac contra-
ctile output (Toepfer et al. 2013). The finding that RLC
phosphorylation accelerates the transition from weakly
to strongly bound cross-bridges is compatible with the
observed increase in force and power produced during
shortening, as well as with the increase in maximal
unloaded shortening velocity seen with enriched RLC
phosphorylation (Toepfer et al. 2013).
In the context of twitch contractions at lower
physiological calcium activations in the myocardium,
an increasing RLC phosphorylation may increase the
calcium sensitivity of contraction and create greater thin
filament activation at lower calcium levels. This would be
mediated by co-operative activation of the thin filament
created by RLC phosphorylation, allowing for the faster
attachment of cross-bridges. Additional studies should
aim to investigate this effect in submaximal calcium
concentrations with this experimental system.
Conclusions
Under conditions where myosin heads are largely syn-
chronized (post rapid release protocol) or unsynchronized
(post release ramp protocol), RLC phosphorylation alters
ktr. SL alters ktr on a beat-to-beat basis because it is affected
by ventricular pre-load causing myocardial stretching.
RLC phosphorylation adds another level of regulation
on ktr, which is observed under chronic conditions of
pre-load, which probably comprises a more long-term
mechanism for fine-tuning myocardial contractility. In
models of disease that are caused by reductions in RLC
phosphorylation, the phenotype of ineffectual muscle
contraction is brought about by reduced cross-bridge
cycling rates and a reduction in actively cycling
cross-bridges (N). Our results complement these findings,
highlighting RLC phosphorylation as being a thick
filament level regulator of the Frank–Starling law of the
heart, which is independent of the thin filament regulatory
complex.We suggest thatRLCphosphorylationmodulates
the Frank–Starling law of the heart in both health and
disease. It does so by adapting myocardial contractile
kinetics, allowing for the timely systolic expulsion of
ventricular pre-load.
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